

APR 20 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Giblin et al.  
Serial No.: To Be Assigned Group Art Unit:  
File Date: October 6, 2004 Examiner:  
For: Heterocyclyl Compounds

Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: Reference #9  
☐ Copies of the references were submitted in parent application \_\_\_\_\_ (37 CFR 1.98(d))  
☒ A copy of the International Search Report which issued on International Application No. PCT/EP2004/011366 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:  
(1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):


80611  
MAR 20 2006

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

  
\_\_\_\_\_  
J. Scott Young  
Registration No. 45,582

Date: Apr 27, 2006  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8160  
Facsimile: (919) 483-7988

|  |  |                                      |                              |
|--|--|--------------------------------------|------------------------------|
| Form PTO-1449  | U.S. Department of Commerce<br>Patent and Trademark Office | ATTY DOCKET NO.<br>PB60531USW        | SERIAL NO.<br>To Be Assigned |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use several sheets if necessary)</i> |  | APPLICANT<br>GIBLIN et al.           |                              |
|  |  | FILING DATE<br>Concurrently Herewith | GROUP                        |

## U.S. PATENT DOCUMENTS

| Examiner Initials |   | Document Number | Date         | Name            | Class | Subclass | Filing Date If Appropriate |
|-------------------|---|-----------------|--------------|-----------------|-------|----------|----------------------------|
|                   | 1 | US-5 663 180-A  | 02 -09 -1997 | Reitz DB et al. |       |          |                            |
|                   | 2 | US-5 723 483-A  | 03 -03 -1998 | Labeeuw et al.  |       |          |                            |
|                   | 3 | US-5 811 459-A  | 09 -22 -1998 | Breault et al.  |       |          |                            |
|                   | 4 | US-6 492 411-B1 | 12 -10 -2002 | Talley et al.   |       |          |                            |
|                   |   |                 |              |                 |       |          |                            |
|                   |   |                 |              |                 |       |          |                            |
|                   |   |                 |              |                 |       |          |                            |
|                   |   |                 |              |                 |       |          |                            |

## FOREIGN PATENT DOCUMENTS

|  |    | Document Number | Date         | Country | Class | Subclass | Translation<br>Yes No |  |
|--|----|-----------------|--------------|---------|-------|----------|-----------------------|--|
|  | 5  | EP-0 647 629-A  | 04 -12 -1995 | EP      |       |          |                       |  |
|  | 6  | EP-0 752 421-A  | 01 -08 -1997 | EP      |       |          |                       |  |
|  | 7  | EP-1 270 559-A  | 01 -02 -2003 | EP      |       |          |                       |  |
|  | 8  | WO-01/19814-A2  | 03 -22 -2001 | WO      |       |          |                       |  |
|  | 9  | WO-03/084917-A  | 10 -16 -2003 | WO      |       |          |                       |  |
|  | 10 | WO-03/101959-A1 | 12 -11 -2003 | WO      |       |          |                       |  |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

|  |    |   |
|--|----|---|
|  | 11 | Pathan et al., Journal of the Institution of Chemists (India); 72 (5); 190-191;   |
|  | 12 | KARIG GUNTER; Directed Deprotonation-Transmetalation as a Route to Substituted Pyridines; Organic Letters; 2001; 3 (6); 835-838;  |
|  | 13 | PATHAN M D ET AL; 514183; Chemical Abstracts Service; 2001;   |
|  | 14 | RAHIM ABDUR M ET AL; Isomeric acetoxy analogues of rofecoxib: A novel class of highly potent and selective cyclooxygenase-2 inhibitors; Bioorganic and Medicinal Chemistry Letters; 2002; 12 (19); 2753-2756; |
|  | 15 | REBSTOCK ANNE-SOPHIE; Synthesis and deprotonation of 2-(pyridyl)phenols and 2-(pyridyl)anilines; Organic and Biomolecular Chemistry; 2003; 17; 3064-3068;   |
|  | 16 | ROSENBERG SAUL H ET AL; Convergent and efficient synthesis of spiro[benzofuran-3(2H),4'-piperidines]; Journal of Organic Chemistry; 1984; 49 (1); 56-62;  |

|  |                 |
|--|-----------------|
| Examiner Signature   | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |

|  |  |                                      |                                     |
|--|--|--------------------------------------|-------------------------------------|
| Form PTO-1449  | U.S. Department of Commerce<br>Patent and Trademark Office | ATTY DOCKET NO.<br>PB60531USW        | SERIAL NO. 720012<br>To Be Assigned |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use several sheets if necessary)</i> |  | APPLICANT<br>GIBLIN et al.           |                                     |
|  |  | FILING DATE<br>Concurrently Herewith | GROUP                               |

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc)

|  |  |   |
|--|--|---|
|  |  | TRIVEDI G S ET AL; Indian Journal of Chemistry; 1992; 31B; 366-369; |
|  |  |   |
|  |  |   |
|  |  |   |
|  |  |   |
|  |  |   |

|   |                 |
|---|-----------------|
| Examiner Signature  | Date Considered |
| <p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> |                 |